Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...

Here are today's Five Things You Need to Know in Boston business news, including earthquakes, an AI bubble, stock crash, spurned suitors and multibillion-dollar M&A deals.

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Recent health news includes significant developments such as Akero Therapeutics' promising liver disease drug, potential ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.08 or 1.14% from the prior close of $7.02. The stock opened at $7.02 and touched ...